Skip to Content
MilliporeSigma
All Photos(1)

Documents

CDS022971

Sigma-Aldrich

Lapatinib

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C29H26ClFN4O4S
CAS Number:
231277-92-2
Molecular Weight:
581.06
MDL number:
MFCD09264194
UNSPSC Code:
12352200
PubChem Substance ID:
329796232

description

AldrichCPR

form

solid

SMILES string

CS(=O)(CCNCC1=CC=C(C2=CC=C3N=CN=C(C3=C2)NC4=CC=C(C(Cl)=C4)OCC5=CC=CC(F)=C5)O1)=O

InChI

1S/C29H26ClFN4O4S/c1-40(36,37)12-11-32-16-23-7-10-27(39-23)20-5-8-26-24(14-20)29(34-18-33-26)35-22-6-9-28(25(30)15-22)38-17-19-3-2-4-21(31)13-19/h2-10,13-15,18,32H,11-12,16-17H2,1H3,(H,33,34,35)

InChI key

BCFGMOOMADDAQU-UHFFFAOYSA-N

Gene Information

human ... EGFR(1956) , ERBB2(2064)

Looking for similar products? Visit Product Comparison Guide

General description

Lapatinib is a tyrosine kinase inhibitor, targeting both the epidermal growth factor receptors, ErbB1 and ErbB-2. In combination with trastuzumab, it is reported to show complementary mechanisms of action and synergistic antitumor activity in breast cancer.

Other Notes

Please note that Sigma-Aldrich provides this product to early discovery researchers as part of a collection of unique chemicals. Sigma-Aldrich does not collect analytical data for this product. Buyer assumes responsibility to confirm product identity and/or purity. All sales are final.

NOTWITHSTANDING ANY CONTRARY PROVISION CONTAINED IN SIGMA-ALDRICH′S STANDARD TERMS AND CONDITIONS OF SALE OR AN AGREEMENT BETWEEN SIGMA-ALDRICH AND BUYER, SIGMA-ALDRICH SELLS THIS PRODUCT "AS-IS" AND MAKES NO REPRESENTATION OR WARRANTY WHATSOEVER WITH RESPECT TO THIS PRODUCT, INCLUDING ANY (A) WARRANTY OF MERCHANTABILITY, (B) WARRANTY OF FITNESS FOR A PARTICULAR PURPOSE, OR (C) WARRANTY AGAINST INFRINGEMENT OF INTELLECTUAL PROPERTY RIGHTS OF A THIRD PARTY, WHETHER ARISING BY LAW, COURSE OF DEALING, COURSE OF PERFORMANCE, USAGE OF TRADE OR OTHERWISE.

pictograms

Exclamation mark
GHS07

signalword

Warning

Hazard Classifications

Aquatic Chronic 4 - Eye Irrit. 2 - Lact.

Storage Class

11 - Combustible Solids

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Customers Also Viewed

Slide 1 of 10

1 of 10

JNK-IN-8 ≥96% (HPLC)

Sigma-Aldrich

SML1246

JNK-IN-8

Axitinib ≥98% (HPLC)

Sigma-Aldrich

PZ0193

Axitinib

Bosutinib ≥98% (HPLC)

Sigma-Aldrich

PZ0192

Bosutinib

Dasatinib

Sigma-Aldrich

CDS023389

Dasatinib

Sorafenib European Pharmacopoeia (EP) Reference Standard

Y0002098

Sorafenib

PHTPP ≥98% (HPLC)

Sigma-Aldrich

SML1355

PHTPP

Crizotinib ≥98% (HPLC)

Sigma-Aldrich

PZ0191

Crizotinib

Capecitabine ≥98% (HPLC)

Sigma-Aldrich

SML0653

Capecitabine

Saquinavir mesylate ≥98% (HPLC), powder

Sigma-Aldrich

S8451

Saquinavir mesylate

Imatinib

Sigma-Aldrich

CDS022173

Imatinib

Melinda Halasz et al.
Science signaling, 9(455), ra114-ra114 (2016-11-24)
Signal transduction networks are often rewired in cancer cells. Identifying these alterations will enable more effective cancer treatment. We developed a computational framework that can identify, reconstruct, and mechanistically model these rewired networks from noisy and incomplete perturbation response data
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial
Baselga J, et al.
The Lancet, 379(9816), 633-640 (2012)
Sydney M Shaffer et al.
Nature, 546(7658), 431-435 (2017-06-14)
Therapies that target signalling molecules that are mutated in cancers can often have substantial short-term effects, but the emergence of resistant cancer cells is a major barrier to full cures. Resistance can result from secondary mutations, but in other cases
Tushar Piyush et al.
Cell death and differentiation, 24(11), 1937-1947 (2017-07-22)
Epidermal growth factor receptor (EGFR) is an important regulator of epithelial cell growth and survival in normal and cancerous tissues and is a principal therapeutic target for cancer treatment. EGFR is associated in epithelial cells with the heavily glycosylated transmembrane
Denis M Collins et al.
Cellular immunology, 319, 35-42 (2017-07-25)
Trastuzumab is an anti-HER2 monoclonal antibody (mAb) therapy capable of antibody-dependent cell-mediated cytotoxicity (ADCC) and used in the treatment of HER2+ breast cancer. Through interactions with FcƴR+ immune cell subsets, trastuzumab functions as a passive immunotherapy. The EGFR/HER2-targeting tyrosine kinase
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service